[go: up one dir, main page]

AR048460A1 - TREATMENT OF RESPIRATORY FUNCTION ALTERED WITH GABOXADOL - Google Patents

TREATMENT OF RESPIRATORY FUNCTION ALTERED WITH GABOXADOL

Info

Publication number
AR048460A1
AR048460A1 ARP050101300A ARP050101300A AR048460A1 AR 048460 A1 AR048460 A1 AR 048460A1 AR P050101300 A ARP050101300 A AR P050101300A AR P050101300 A ARP050101300 A AR P050101300A AR 048460 A1 AR048460 A1 AR 048460A1
Authority
AR
Argentina
Prior art keywords
treatment
gaboxadol
respiratory function
sleep apnea
function altered
Prior art date
Application number
ARP050101300A
Other languages
Spanish (es)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of AR048460A1 publication Critical patent/AR048460A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Metodo para el tratamiento de la alteracion respiratoria en un paciente que sufre apnea del sueno, tal como apnea central del sueno o apnea obstructiva del sueno, que incluye la administracion de una cantidad efectiva de gaboxadol por día al paciente mencionado. Composicion farmacéutica.Method for the treatment of respiratory disturbance in a patient suffering from sleep apnea, such as central sleep apnea or obstructive sleep apnea, which includes the administration of an effective amount of gaboxadol per day to the mentioned patient. Pharmaceutical composition

ARP050101300A 2004-04-02 2005-04-01 TREATMENT OF RESPIRATORY FUNCTION ALTERED WITH GABOXADOL AR048460A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200400540 2004-04-02

Publications (1)

Publication Number Publication Date
AR048460A1 true AR048460A1 (en) 2006-04-26

Family

ID=36608890

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050101300A AR048460A1 (en) 2004-04-02 2005-04-01 TREATMENT OF RESPIRATORY FUNCTION ALTERED WITH GABOXADOL

Country Status (6)

Country Link
KR (1) KR20070010136A (en)
CN (1) CN1942185A (en)
AR (1) AR048460A1 (en)
EA (1) EA200601853A1 (en)
IL (1) IL178289A0 (en)
ZA (1) ZA200607427B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240160666A (en) * 2015-07-17 2024-11-11 오비드 테라퓨틱스 인크. Methods of treating developmental disorders with gaboxadol
AU2018309049A1 (en) * 2017-08-04 2020-02-27 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of diabetes and related conditions
EP3883566A4 (en) 2018-11-21 2022-09-07 Certego Therapeutics Inc. GABOXADOL FOR SUICIDE RISK REDUCTION AND RAPID DEPRESSION RELIEF

Also Published As

Publication number Publication date
EA200601853A1 (en) 2007-02-27
ZA200607427B (en) 2009-02-25
CN1942185A (en) 2007-04-04
IL178289A0 (en) 2007-03-08
KR20070010136A (en) 2007-01-22

Similar Documents

Publication Publication Date Title
IL201479A (en) Use of tapentadol for the manufacture of a medicament for the treatment of pain
UA109878C2 (en) Isoquinolinone derivatives, pharmaceutical composition based on them (variants), and method of treating diseases (variants)
UY30901A (en) NEW METHODS
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
MX2010002498A (en) Methods of treating or preventing respiratory tract infection comprising administering cholecalciferol.
PL2134704T3 (en) Compounds and compositions as modulators of gpr119 activity
CO6361917A2 (en) TREATMENT OF DIABETES IN PATIENTS WITH INSUFFICIENT GLUCEMIC CONTROL TO WEIGHT THERAPY WITH AN ORAL OR NON-ORAL ANTIDIABETIC PHARMACO
MX2009013989A (en) Combination therapy for depression.
PH12013501790B1 (en) Use of dpp iv inhibitors
MX2008013304A (en) Glp-1 compounds.
MX2010005631A (en) Novel cyclic hydrocarbon compounds for the treatment of diseases.
MX2010002736A (en) 1-amino-alkylcyclohexane derivatives for the treatment of cochlear tinnitus.
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
BR112015022465A2 (en) Non-toxic treatment method for drug withdrawal syndrome
IN2012DN02471A (en)
MX2010006204A (en) 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressine-dependent diseases.
TNSN07263A1 (en) Substituted 4-phenyl tetrahydroisoquinolines, methods for producing them, their use as drug, and drug containing them
UA97401C2 (en) Improved taste-masking extrudates
NZ595364A (en) TISSUE KALLIKREIN FOR THE TREATMENT OF PANCREATIC beta-CELL DYSFUNCTION
MX355015B (en) Use of indolyl and indolinyl hydroxamates for treating heart failure of neuronal injury.
AR079000A1 (en) ANTI-BANK THERAPY AIMED AT CANCEROSA MOTHER RESISTANT DRUG CELLS
TN2010000266A1 (en) Oxazolidinones for the treatment and/or prophylaxis of heart failure
AR048460A1 (en) TREATMENT OF RESPIRATORY FUNCTION ALTERED WITH GABOXADOL
UY30557A1 (en) TREATMENT AND PREVENTION OF INTESTINAL FIBROSIS
ATE527997T1 (en) USE OF AMINAPTHONE IN THE PRODUCTION OF A MEDICATION FOR THE TREATMENT OF ARTERIOPATHIES

Legal Events

Date Code Title Description
FB Suspension of granting procedure